CLL BTK Inhibitor Tx and AE Guide

CME

Global Perspectives and Clinical Resources to Guide Treatment Decisions and Management of Adverse Events With BTK Inhibitor Therapy in CLL 

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: March 13, 2025

Expiration: September 12, 2025

Activity

Progress
1 2
Course Completed

References

  1. Lewis KL, Cheah CY. Non-covalent BTK inhibitor--the new BTKids on the block for B-cell malignancies. J Pers Med. 2021;11:764.
  2. Montoya S, Thompson MC. Non-covalent Bruton’s tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Cancers (Basel). 2023;15:3648.
  3. Pirtobrutinib [prescribing information]. Indianapolis, IN: Eli Lilly; 2023.
  4. Kaptein A, de Bruin Gerjan, Emelot-van Hoek M, et al. Potency and selectivity of BTK inhibitors in clinical development for B-cell malignancies. Presented at: 60th American Society of Hematology Annual Meeting and Exposition; December 1-4, 2018. Abstract 1871.
  5. Woyach JA, Furman RR, Liu T-M, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370:2286-2294.
  6. Woyach JA, Ruppert AS, Guinn D, et al. BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017;35:1437-1443.
  7. Tam C, Thompson PA. BTK inhibitors in CLL: second-generation drugs and beyond. Blood Adv. 2024;8:2300-2309.
  8. Gu D, Tang H, Wu J, et al. Targeting bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies. J Hematol Oncol. 2021;14:40.
  9. Wang E, Mi Xiaoli, Thomson MC, et al. Mechanisms of resistance to noncovalent Bruton’s tyrosine kinase inhibitors. N Engl J Med. 2022;386:736-743.
  10. Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397:892-901.
  11. Mato AR, Flinn IW, Pagel JM, et al. Results from a first-in-human, proof-of concept phase I trial in pretreated B-cell malignancies for Loxo-305, a next-generation, highly selective, non-covalent BTK inhibitor. Presented at: 61st American Society of Hematology Annual Meeting and Exposition; December 7-10, 2019. Abstract 501.
  12. Robak T, Witkowska M, Smolewski P. The role of Bruton’s kinase inhibitors in chronic lymphocytic leukemia: current status and future directions. Cancers (Basel). 2022;14:771.
  13. Brandhuber B, Gomez E, Smith S, et al. LOXO-305, a next generation non-covalent BTK inhibitor, for overcoming acquired resistance to covalent BTK inhibitors. Presented at: 6th Annual Meeting of the Society of Hematologic Oncology; September 12-15, 2018. Abstract CLL-200.
  14. Gomez EB, Ebata K, Randeria HS, et al. Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor. Blood. 2023;142:62-72.
  15. Woyach JA, Ruppert A, Heerema NA, et al. Ibrutibib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379:2517-2528.
  16. Woyach JA, Perez G, Ruppert AS, et al. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood. 2024;143:1616.
  17. Galitzia A, Maccaferri M, Mauro FR, et al. Chronic lymphocytic leukemia: management of adverse events in the era of targeted agents. Cancers (Basel). 2024;16:1996.
  18. Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program. 2020;2020:336-345.
  19. Ruppert AS, Booth AM, Ding W, et al. Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. Leukemia. 2021;35:2854-2861.
  20. Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395:1278-1291.
  21. Sharman JP, Egyed M, Jurczak W, et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leukemia. 2022;36:1171-1175.
  22. Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib ± obinutuzumab vs obinutuzumab + chlorambucil in treatment-naive chronic lymphocytic leukemia: 6-year follow-up of Elevate-TN. Presented at: 65th American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract 636.
  23. Shadman M, Munir T, Robak T, et al. Zanubrutinib versus bendamustine and rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: median 5-year follow-up of SEQUOIA. J Clin Oncol. 2025;43:780-787.
  24. Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23:1031-1043.
  25. Al-Sawaf O, Zhang C, Jin HY, et al. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Nat Commun. 2023;14:2147.
  26. Al-Sawaf O, Robrecht S, Zhang C, et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study. Blood. 2024;144:1924-1935.
  27. Tausch E, Schneider C, Stilgenbauer S. Risk-stratification in frontline CLL therapy: standard of care. Hematology Am Soc Hematol Educ Program. 2024;2024:457-466.
  28. Barr PM, Owen C, Robak T, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6:3440-3450.
  29. Moreno C, Greil R, Demirkan F, et al. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. Haematologica. 2022;107:2108-2120.
  30. Shanafelt TD, Wang XV, Hanson CA, et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022;140:112-120.
  31. Hillmen P, Pitchford A, Bloor A, et al. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24:535-552.
  32. Al-Sawaf O, Zhang C, Lu T, et al. Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study. J Clin Oncol. 2021;39:4049-4060.
  33. Fürstenau M, Kater AP, Robrecht S, et al. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2024;25:744-759.
  34. Niemann CU, Munir T, Moreno C, et al. Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24:1423-1433.
  35. Munir T, Cairns DA, Bloor A, et al; National Cancer Research Institute Chronic Lymphocytic Leukemia Subgroup. Chronic lymphocytic leukemia therapy guided by measurable residual disease. N Engl J Med. 2024;390:326-337.
  36. Munir T, Brown JR, O’Brien S, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94:1353-1363.
  37. Kater A, Harrup R, Kipps TJ, et al. Final 7-year follow up and retreatment substudy analysis of MURANO: venetoclax-rituximab (venr)-treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL). Presented at: 28th Annual Congress of the European Hematology Association; June 8-11, 2023. Abstract S201.
  38. Byrd JC, Hillmen P, Ghia P, et al. First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2021;39(15 suppl):7500.
  39. Brown JR, Eichhorst B, Lamanna N, et al. Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE. Blood. 2024;144:2706-2717.
  40. Seymour JF, Kipps TJ, Eichhorst BF, et al. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood. 2022;140:839-850.
  41. Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39:3441-3452.
  42. Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107-1120.
  43. Venetoclax [prescribing information]. San Francisco, CA: Genentech; 2024.
  44. Venetoclax [producto information]. Ludwigshafen, Germany: AbbVie Deutschland; 2025.
  45. Sharman JP, Munir T, Grosicki S, et al. BRUIN CLL-321: randomized phase III trial of pirtobrutinib versus idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma. Presented at: 66th American Society of Hematology Annual Meeting and Exposition; December 7-10, 2024. Abstract 886.
  46. Follows G, Burke JM, Grosicki S, et al. BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol. 2023;41(16 suppl):TPS7582.
  47. Wierda WG, Barr PM, Siddiqi T, et al. Fixed-duration (FD) ibrutinib (I) + venetoclax (V) for first-line (1L) treatment (tx) of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): three-year follow-up from the FD cohort of the phase 2 CAPTIVATE study. J Clin Oncol. 2022;40(16 suppl):7519.
  48. Wierda WG, Jacobs R, Barr PM, et al. Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): up to 5.5 years of follow-up in the phase 2 CAPTIVATE study. J Clin Oncol. 2024;42(16 suppl):7009.
  49. Hillmen P, Pitchford A, Bloor A, et al. The combination of ibrutinib plus venetoclax results in a high rate of MRD negativity in previously untreated CLL: the results of the planned interim analysis of the phase III NCRI FLAIR trial. Presented at: 27th Annual Congress of the European Hematology Association; June 9-12, 2022. Abstract S145.
  50. Ibrutinib [summary of product characteristics]. Beerse, Belgium: Janssen-Cilag International; 2024.
  51. Munir T, Moreno C, Owen C, et al. First prospective data on minimal residual disease (MRD) outcomes after fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of CLL in elderly or unfit patients: the GLOW study. Presented at: 63rd American Society of Hematology Annual Meeting and Exposition; December 11-14, 2021. Abstract 70.
  52. Kater AP, Owen C, Moreno C, et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evid. 2022;1:EVIDoa2200006.
  53. Morena C, Munir T, Owen C, et al. First-line fixed-duration ibrutinib plus venetoclax (Ibr+Ven) vs chlorambucil plus obinutuzumab (Clb+O): 55-month follow-up from the GLOW study. Presented at: 12th Annual Meeting of the Society of Hematologic Oncology 2024 Annual Meeting; September 4-7, 2024. Abstract CLL-487.
  54. Brown JR, Seymour JF, Jurczak W, et al. Fixed-duration acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of chronic lymphocytic leukemia: interim analysis of the multicenter, open-label, randomized, phase 3 AMPLIFY trial. Presented at: 66th American Society of Hematology Annual Meeting and Exposition; December 7-10, 2024. Abstract 1009.
  55. Ibrutinib [prescribing information]. Horsham, PA: Janssen Biotech; South San Francisco, CA: Pharmacyclics; 2024.
  56. Acalabrutinib [summary of product characteristics]. Södertälje, Sweden: AstraZeneca; 2024.
  57. Acalabrutinib [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2025
  58. Zanubrutinib [summary of product characteristics]. Dublin, Ireland: BeiGene Ireland; 2024
  59. Zanubrutinib [prescribing information]. San Mateo, CA: BeiGene USA. 2025.
  60. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: chronic lymphocytic leukemia/small lymphocytic lymphoma. v.2.2025. nccn.org. Accessed February 26, 2025.
  61. O'Brien SM, Brown JR, Byrd JC, et al. Monitoring and managing BTK inhibitor treatment-related adverse events in clinical practice. Front Oncol. 2021;11:720704.